TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14994114
Drug: 0.2 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 percent isosorbide dinitrate ointment
Study: 12074178
Drug: Low-NaFeEDTA group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-NaFeEDTA group (consuming fortified soy sauce, providing 5 mg Fe/day)
Study: 12074178
Drug: High-NaFeEDTA group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-NaFeEDTA group (consuming fortified soy sauce, providing 20 mg Fe/day)
Study: 9844789
Drug: Dihydrexidine (full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrexidine (full D1 receptor agonist), single intravenous doses ranging from 2 mg to a maximum of 70 mg infused over 15 or 120 minutes
Study: 9844789
Drug: Dihydrexidine (full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrexidine (full D1 receptor agonist)
Study: 7865640
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily for 5 days
Study: 7865640
Drug: Dosing after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing after food
Study: 2556456
Drug: Enalapril, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 80 mg/day
Study: 4331769
Drug: Kethoxal 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kethoxal 2.5% cream
Study: 25297637
Drug: PEG‐IFN‐SA (1.5 μg kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN‐SA (1.5 μg kg(‐1) s.c.)
Study: 25297637
Drug: peginterferon‐α‐2a (180 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon‐α‐2a (180 μg s.c.)
Study: 19289135
Drug: Treadmill-walking exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treadmill-walking exercise (twice weekly for 8 weeks)
Study: 28561192
Drug: No cardiovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cardiovascular medication
Study: 28561192
Drug: Peripherally acting
Normalized name: Peripherally acting antiobesity products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripherally acting medication
Study: 28561192
Drug: Centrally acting
Normalized name: Other centrally acting agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrally acting medication
Study: 25565587
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care along with receipt of twice‐daily supportive SMS text messages during the second and third week of the study
Study: 8921775
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E within the drug group
Study: 8921775
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C within the drug group
Study: 1715740
Drug: FK506 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK506 with low-dose steroids
Study: 385873
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg oxaprozin given as a single daily dose
Study: 385873
Drug: 3,900 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,900 mg ASA given in 4 equally divided doses
Study: 24381967
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d of memantine
Study: 24381967
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alpha tocopherol and memantine
Study: 20024737
Drug: Discussion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discussion of oral health with HIV primary care providers
Study: 20024737
Drug: Illicit drug
Normalized name: Illicium difengpi bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Illicit drug use among men
Study: 16400234
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with aluminium hydroxide adsorbed house dust mite allergoid
Study: 29688838
Drug: Intense Pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense Pulsed Light (IPL) treatment applied directly on the eyelids, with three treatments at 4-week intervals.
Study: 29688838
Drug: Sham IPL
Normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham IPL treatment (control group).
Study: 28556458
Drug: Behaviour change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour change intervention (provision of hardware: bin for solid waste, 4 l flushing bucket, 70 l water reservoir; behaviour change communication: compound meetings, interpersonal household sessions, signs depicting rules for toilet use)
Study: 20865582
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion at 0.5 mcg/kg/hour during operation
Study: 19045962
Drug: Problem-solving treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving treatment for primary care (PST-PC)
Study: 3074776
Drug: Subcutaneous corrugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous corrugated drains
Study: 31796304
Drug: Remifentanil 1μg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1μg.kg‐1 bolus + 0.15μg.kg‐1.min‐1 infusion (stopped after skin incision)
Study: 19087756
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (10 sessions)
Study: 19087756
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy and Control
Study: 11762564
Drug: Midazolam oral
Normalized name: midazolam Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam oral syrup administration
Study: 11762564
Drug: Midazolam intravenous
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam intravenous administration
Study: 11762564
Drug: Midazolam bioavailability
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam bioavailability
Study: 11762564
Drug: Initial oral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial oral dose of midazolam
Study: 8149521
Drug: Hirudin (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (0.05, 0.10, 0.20, or 0.30 mg.kg‐1.h‐1 infusion)
Study: 8149521
Drug: Heparin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (target aPTT of 65 to 90 or 90 to 110 seconds)
Study: 29474588
Drug: No reperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No reperfusion therapy (Control)
Study: 14516802
Drug: Atropine treatment
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine treatment
Study: 8942345
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 2 mg h‐1 (n = 12)
Study: 8942345
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 1 mg h‐1 (n = 12)
Study: 22705118
Drug: Biweekly combination
Normalized name: Biweekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly combination therapy with gemcitabine (1000 mg/m²) and carboplatin (AUC 3) on days 1 and 15, every 4 weeks
Study: 22705118
Drug: Gemcitabine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine monotherapy (1000 mg/m²) on days 1, 8, and 15, every 4 weeks
Study: 11349793
Drug: Local pulsated
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local pulsated pressure treatment
Study: 10443310
Drug: Anti-GPIIb/IIIa molecules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-GPIIb/IIIa molecules
Study: 10443310
Drug: Classical anti-aggregant
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical anti-aggregant drugs
Study: 2085099
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein formula (1.1 g/100 ml)
Study: 2085099
Drug: Conventional protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional protein formula (1.5 g/100 ml)
Study: 377971
Drug: Cefazolin, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin, 1.0 gm administered intramuscularly and cephalothin, 2.0 gm administered intravenously at 6, 12, and 24 hours postoperatively
Study: 27046159
Drug: Continued thienopyridine
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued thienopyridine and aspirin after 12 months
Study: 27046159
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and aspirin after 12 months
Study: 6863579
Drug: Amiloride-hydrochlorothiazide 5/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride-hydrochlorothiazide 5/50 mg/day
Study: 6863579
Drug: Timolol 20
Normalized name: timolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 20 mg/day
Study: 6863579
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of timolol with hydrochlorothiazide
Study: 6863579
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of timolol with amiloride-hydrochlorothiazide
Study: 28986164
Drug: Rosiglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone treatment in T2D subjects
Study: 28986164
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment in T2D subjects
Study: 28986164
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (T2D subjects before treatment)
Study: 19629848
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (using plain glasses)
Study: 24139829
Drug: Sublingual allergen
Normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual allergen immunotherapy (SLIT)
Study: 24139829
Drug: Subcutaneous allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous allergen immunotherapy (SCIT)
Study: 15855490
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) in addition to current combination therapy for 4 weeks
Study: 10918432
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron (2 mg, 1 h before first daily fraction of radiation)
Study: 10918432
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron (8 mg, 1.5 h prior to each fraction of TBI)
Study: 10918432
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group (no 5-HT3-receptor antagonist)
Study: 6743606
Drug: External cephalic
Normalized name: Cephaelis ipecacuanha preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: External cephalic version under tocolysis with intravenous ritodrine
Study: 31568714
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of XEN1101
Study: 24993981
Drug: High-ceiling sulphonamide
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-ceiling sulphonamide diuretics
Study: 24993981
Drug: Medication acting
Normalized name: sodium fluoride Mouthwash [ACT Fluoride Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication acting via the renin-angiotensin system
Study: 24993981
Drug: Non-selective β-blockers
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective β-blockers
Study: 15793108
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of 1 g every 8 h for 24 h
Study: 15793108
Drug: 3-h infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-h infusion of 1 g every 8 h for 24 h
Study: 15793108
Drug: 3-h infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-h infusion of 2 g every 8 h for 24 h
Study: 11789238
Drug: Shenmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai injection (intravenous for 7 days)
Study: 11789238
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Shenmai injection)
Study: 23943316
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine (DFO) at 62 mg/kg/day (up to a maximum daily dose of 6000 mg/day)
Study: 21428978
Drug: Cortexolone 17α-propionate
Normalized name: Cortexolone 17α-propionate
DrugBank: Clascoterone (DB12499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cortexolone 17α-propionate 1% cream
Study: 21428978
Drug: Tretinoin 0·05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0·05% cream
Study: 15017644
Drug: Collaborative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative treatment (gastroenterologist and psychologist working together)
Study: 15017644
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment directed at gastrointestinal function
Study: 9351621
Drug: Budesonide dry
Normalized name: budesonide Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide dry powder, 800 microg twice daily, delivered from a Turbuhaler
Study: 21403595
Drug: Low-intensity whole
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity whole body vibration (15 mins, 30 Hz, 0.3 g)
Study: 21403595
Drug: Higher intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher intensity whole body vibration (2 × 3 mins, 12.5 Hz, 1 g)
Study: 18602742
Drug: Adjuvant radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiation treatment (ART) with 60 Gray (Gy)
Study: 18602742
Drug: Adjuvant radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiation treatment (ART) with 60-64 Gy
Study: 18602742
Drug: Adjuvant radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiation treatment (ART)
Study: 16645533
Drug: Nomegestrol acetate
Normalized name: nomegestrol acetate
DrugBank: Nomegestrol acetate (DB13981)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Nomegestrol acetate (NOMAc; 5 mg/day for 10 days x month for 12 months) plus calcium (1 g/day)
Study: 12819322
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitor (ramipril)
Study: 12819322
Drug: Dihydropyridine calcium
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydropyridine calcium channel blocker (amlodipine)
Study: 8795307
Drug: Systemic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic infusion via the brachial vein (Group S)
Study: 8795307
Drug: Ipsipedal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipsipedal infusion via the dorsalis pedis vein (Group IP)
Study: 3217807
Drug: Vindesine (VDS)
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (VDS) 4 mg/m2 IV weekly X 8, then every second week
Study: 3217807
Drug: Lomustine (CCNU)
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomustine (CCNU) 70 mg/m2 orally, cyclophosphamide (CTX) 1000 mg/m2 IV every 4 weeks, methotrexate (MTX) 20 mg/m2 orally days 15 and 18 of each course
Study: 3217807
Drug: CCNU +
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCNU + CTX + MTX + VDS (lower doses: CCNU 50 mg/m2, CTX 750 mg/m2, VDS 2 mg/m2)
Study: 29875101
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day quizartinib
Study: 29875101
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day quizartinib
Study: 26150601
Drug: SB4 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB4 (50 mg subcutaneous weekly)
Study: 26150601
Drug: ETN (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN (50 mg subcutaneous weekly)
Study: 26776356
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant patch (FSP; TachoSil)
Study: 21216835
Drug: Tacrolimus monotherapy
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus monotherapy (MONO)
Study: 17919618
Drug: Tacrolimus combination
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus combination therapy (COMBO)
Study: 9764968
Drug: L-NMMA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (4 mg kg(‐1) h(‐1) continuous infusion with a front loaded bolus of 4 mg kg(‐1))
Study: 2238184
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg bendrofluazide
Study: 2238184
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg bendrofluazide
Study: 2238184
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg bendrofluazide
Study: 2238184
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg bendrofluazide
Study: 2238184
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bendrofluazide
Study: 360764
Drug: Oral norephedrine
Normalized name: Norephedrine
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral norephedrine
Study: 26363720
Drug: Lurasidone 20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 20-60 mg or 80-120 mg
Study: 26363720
Drug: Lurasidone (continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (continuation treatment)
Study: 24108252
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (0-80 mg)
Study: 24108252
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (doses >40 mg)
Study: 21382516
Drug: Community Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Care (CC) - 6 month SDT-based intervention
Study: 21382516
Drug: Harm Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harm Reduction (HR) - Extended need support with medication recommendation
Study: 18974068
Drug: Activator-headgear appliance
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activator-headgear appliance for at least 9 months followed by fixed appliance therapy
Study: 18974068
Drug: Minor orthodontic
Normalized name: Vinca minor extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minor orthodontic treatment (control group)
Study: 16724576
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg vardenafil plus 0.5 g/kg ethanol
Study: 14606098
Drug: High-dose Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Vitamin C (10 g/day) intravenously for 5 days
Study: 14606098
Drug: Low-dose Vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Vitamin C (1 g/day) intravenously for 5 days
Study: 2024983
Drug: 0.05% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tretinoin therapy
Study: 25041339
Drug: basiliximab +
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: basiliximab + belatacept high dose (HD) + mycophenolate mofetil (MMF)
Study: 25041339
Drug: belatacept low
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: belatacept low dose (LD) + MMF
Study: 22297244
Drug: Everolimus 10mg
Normalized name: EVEROLIMUS 10MG TAB
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 10mg once daily (n=277)
Study: 17372025
Drug: Grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass pollen immunotherapy (Phleum pratense)
Study: 16279148
Drug: Pravastatin (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (specific dosage and duration not mentioned)
Study: 10206118
Drug: MDT +
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MDT + 10 daily doses of 2 x 10(6) IU of recombinant human IFN-gamma/m2 followed by 10 daily doses of 10(7) IU IFN-gamma/m2
Study: 7540413
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody B724
Study: 7540413
Drug: Control ELISAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control ELISAs using polyclonal antibodies
Study: 2230890
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (TIOS II)
Study: 2230890
Drug: Percentage of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percentage of tumor necrosis induced by preoperative chemotherapy
Study: 7150174
Drug: Benactyzine hydrochloride
Normalized name: benactyzine hydrochloride
DrugBank: Benactyzine (DB09023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benactyzine hydrochloride (4.14 mg/70 kg body weight)
Study: 18663319
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (Genotropin) treatment at a median dose of 0.03 mg/kg/day for a median duration of 10.2 years (range 6.9-11.5)